Nixon Peabody Trust Co. Sells 16,730 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Nixon Peabody Trust Co. reduced its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 22.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 57,139 shares of the medical research company's stock after selling 16,730 shares during the quarter. Nixon Peabody Trust Co.'s holdings in IQVIA were worth $11,228,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Smith Group Asset Management LLC acquired a new position in IQVIA during the 4th quarter worth approximately $1,616,000. Simplify Asset Management Inc. raised its stake in IQVIA by 67.8% during the 3rd quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company's stock worth $2,284,000 after buying an additional 3,894 shares during the period. Nordea Investment Management AB raised its stake in IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company's stock worth $277,908,000 after buying an additional 452,029 shares during the period. Hickory Asset Management Inc. purchased a new stake in shares of IQVIA in the fourth quarter worth approximately $941,000. Finally, Fifth Third Bancorp raised its stake in shares of IQVIA by 13.0% in the fourth quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company's stock worth $2,590,000 after purchasing an additional 1,521 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Stock Performance

Shares of IQVIA stock traded up $2.47 during trading hours on Wednesday, reaching $186.04. The company had a trading volume of 1,050,048 shares, compared to its average volume of 1,206,530. IQVIA Holdings Inc. has a one year low of $179.28 and a one year high of $261.73. The business has a fifty day simple moving average of $198.52 and a 200 day simple moving average of $213.86. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The firm has a market cap of $32.76 billion, a PE ratio of 24.81, a price-to-earnings-growth ratio of 1.99 and a beta of 1.48.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on IQV shares. BTIG Research downgraded IQVIA from a "buy" rating to a "neutral" rating in a research note on Monday, February 3rd. Barclays reduced their target price on IQVIA from $255.00 to $235.00 and set an "overweight" rating for the company in a report on Monday, February 3rd. Bank of America reduced their target price on IQVIA from $255.00 to $235.00 and set a "buy" rating for the company in a report on Friday, December 13th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $270.00 target price on shares of IQVIA in a report on Monday, February 10th. Finally, Truist Financial reaffirmed a "buy" rating and issued a $263.00 target price (up from $261.00) on shares of IQVIA in a report on Monday, February 10th. Four research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $249.05.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.